Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.
Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H.
Katsuya Y, et al.
Front Oncol. 2023 Jan 9;12:966527. doi: 10.3389/fonc.2022.966527. eCollection 2022.
Front Oncol. 2023.
PMID: 36698400
Free PMC article.